Read More

Vice President of Business Development for Exela’s CDMO business unit. Matt was previously Vice President Business Development & Marketing for Cytovance Biologics a CDMO and held executive level roles at CDMO’s, Lake Pharma and Nitto Avecia Pharma Services. Prior to that, Matt was Global Vice President of Business Development at Pharm-Olam International, a CRO and President of Datatrak International, a SasS electronic data capture life sciences software company. Matt was Sr. Director Consulting Services for Dell Technologies, for twelve years serving within the Life Sciences & Healthcare business units. Matt has an undergrad from San Diego State University, an MBA
Read More

Aruna Koganti, Ph.D., MBA is Vice President of Regulatory Affairs and Clinical Programs. She joined Exela with more than 14 years of Drug Metabolism and Bioanalytical research experience from Huntingdon Life Sciences, In Vitro Technologies, Covance Laboratories, and Forest Laboratories. She received her Ph.D. from Rutgers University, Piscataway, NJ and her MBA from University of Chicago, Booth School of Business.
Read More

John Maloney, Ph.D., is Senior Vice President of Research & Development. He came to Exela with more than 25 years of Research & Development experience from Sterling Winthrop, Alpharma, Taro Pharmaceuticals, Harmony Labs, Sandoz, and TPDA. Dr. Maloney has developed numerous abbreviated new drug applications (ANDA) for submission to the FDA, and OTC/DESI products for both the US and European markets. He received his Ph.D. from and continued with his Post-Doctoral studies at State University of New York, Buffalo NY.
Read More

Mark Hartman, Exela’s Chief Commercial Officer, is experienced in transforming pharmaceutical companies from contract manufacturers into market leaders and has successfully directed the commercialization of more than 150 pharmaceutical products. Mr. Hartman has over 36 years of experience in global pharmaceutical sales, marketing and management, including proprietary and generic prescription medications, and over-the-counter and nutritional products. Prior to joining Exela, he held positions as President of Dr. Reddy’s Laboratories, Wockhardt USA, and Nesher Pharmaceuticals and Vice-President of Sales and Marketing of Watson Laboratories Generic Division, Director of Marketing at Alpharma, as well as various roles at Lederle Laboratories where he
Read More

SR Murthy Mallipeddi, Ph.D. Founder and Chief Scientific Officer at Exela. Dr. Murthy received his Ph.D. in Pharmaceutical Chemistry from Andhra University, India. He previously served as a Chief of Research & Development and Manufacturing at Medreich Ltd and TTK Healthcare Ltd pharmaceutical companies in India.  Dr. Murthy has developed more than 175 formulations, encompassing oral solids, injectables, ophthalmics, otics and topicals; including several injectable NDA(b)(2) and ANDA formulations currently on the US market.
Read More

Phanesh Koneru, Ph.D., LL.M., is the Founder, President and CEO of Exela Pharma Sciences. He also serves as its General Counsel. Before founding Exela, Phanesh was Vice President, Intellectual Property at Watson Pharmaceuticals (sold ultimately to Allergan & Teva). He also worked at law firms in New York and Palo Alto, CA. Phanesh began his professional career as a registered pharmacist in California and continued for 12 years. Phanesh earned his Ph.D. in Biomedicinal Chemistry from the University of Southern California School of Pharmacy, Juris Doctor (J.D) from the University of San Diego School of Law, and Master of Laws
Read More